Call Text Chat Email Refer a Patient Join a Study

Search

MotherToBaby

Medications and More during pregnancy and breastfeeding

Cariprazine (Vraylar®)

Selected References:

  • Allergan, Inc. 2025. Vraylar Product Label. National Institute of Health DailyMed Database. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm. 
  • Balamurali S, et al. 2026. Cariprazine in Human Milk: Cautionary Implications for Use During Lactation. J Clin Psychopharmacol; doi: 10.1097/JCP.0000000000002174. Epub ahead of print. 
  • Culpepper L, et al. 2022. Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia. Neuropsychiatr Dis Treat; 18: 995-1011.  
  • Herold R, et al. 2024. Cariprazine maintenance treatment during pregnancy – a case report. Front Psychiatry; 15:1421395.  
  • Huybrechts K, et al. 2023. Association of In Utero Antipsychotic Medication Exposure With Risk of Congenital Malformations in Nordic Countries and the US. JAMA Psychiatry: 80(2):156–166.  
  • U.S. FDA. 2015. Vraylar (Cariprazine) pharmacology review. Available at:  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000PharmR.pdf. Accessed May 23, 2024.  

 

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $1,200,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.